Taysha Gene Therapies shared new data on its gene therapy TSHA-102 for Rett syndrome at the 2026 IRSF Scientific Meeting. The data showed sustained functional improvements over 12 months regardless of patient age or disease severity, supporting TSHA-102's potential as a one-time treatment targeting the genetic cause of Rett syndrome. Additional presentations highlighted the developmental plateau in Rett syndrome and validated assessment tools for clinical trials. These findings bolster the ongoing REVEAL pivotal trial and regulatory progress for TSHA-102, which has multiple FDA designations for expedited development.
Woodward, Inc. announced a quarterly cash dividend of $0.32 per share, payable on September 3, 2026, to shareholders of record as of August 20, 2026. This dividend reflects the company's ongoing commitment to returning value to shareholders. Woodward...
EShallGo Inc., a provider of integrated office technology solutions, completed a $1.479 million registered direct offering by selling 454,968 Class A shares at $3.25 each. The funds will support its growth in AI-enabled enterprise applications launch...
MEDIROM MOTHER Labs has expanded its deployment of the REMONY® remote health monitoring system, equipped with the recharge-free MOTHER Bracelet®, in the Japan Ground Self-Defense Force (JGSDF) 8th Division. The additional order triples the scale of t...
A new playground designed by kids and built by volunteers opened at Chimborazo Elementary School in Richmond, serving over 400 students and the wider community. Funded mainly by the CarMax Foundation and supported by KABOOM!, this project aims to add...
Equinox Gold has signed 20-year land access agreements with the three communities hosting its Los Filos Mine in Mexico, enabling the company to begin restarting heap leach operations and advancing technical studies for potential expansion, including ...
